The submission of additional patent applications by Clearmind Medicine is a strategic move to strengthen its position in the rapidly growing psychedelic medicine industry. By securing patents for innovative compounds related to MDMA, Ibogaine, and Ketamine, the company not only protects its research and development efforts but also potentially opens up new avenues for therapeutic applications. This could attract investor interest and positively impact the stock price in the short term, as it demonstrates the company's commitment to innovation and growth in this niche market.